Free Trial
NASDAQ:AGIO

Agios Pharmaceuticals (AGIO) Stock Price, News & Analysis

Agios Pharmaceuticals logo
$27.66 +0.52 (+1.92%)
Closing price 04/17/2025 04:00 PM Eastern
Extended Trading
$27.65 -0.01 (-0.04%)
As of 04/17/2025 04:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Agios Pharmaceuticals Stock (NASDAQ:AGIO)

Key Stats

Today's Range
$26.99
$28.38
50-Day Range
$24.53
$35.54
52-Week Range
$23.42
$62.58
Volume
590,693 shs
Average Volume
711,262 shs
Market Capitalization
$1.58 billion
P/E Ratio
2.44
Dividend Yield
N/A
Price Target
$56.57
Consensus Rating
Moderate Buy

Company Overview

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Agios Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
79th Percentile Overall Score

AGIO MarketRank™: 

Agios Pharmaceuticals scored higher than 79% of companies evaluated by MarketBeat, and ranked 205th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Agios Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.56, and is based on 5 buy ratings, 4 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Agios Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

  • Read more about Agios Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Agios Pharmaceuticals are expected to grow in the coming year, from ($6.85) to ($5.79) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Agios Pharmaceuticals is 2.44, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 21.38.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Agios Pharmaceuticals is 2.44, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 21.84.

  • Price to Book Value per Share Ratio

    Agios Pharmaceuticals has a P/B Ratio of 1.02. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Agios Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    6.43% of the float of Agios Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Agios Pharmaceuticals has a short interest ratio ("days to cover") of 4.8.
  • Change versus previous month

    Short interest in Agios Pharmaceuticals has recently increased by 4.41%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Agios Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Agios Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    6.43% of the float of Agios Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Agios Pharmaceuticals has a short interest ratio ("days to cover") of 4.8.
  • Change versus previous month

    Short interest in Agios Pharmaceuticals has recently increased by 4.41%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Agios Pharmaceuticals has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 13 news articles for Agios Pharmaceuticals this week, compared to 5 articles on an average week.
  • Search Interest

    Only 1 people have searched for AGIO on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added Agios Pharmaceuticals to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Agios Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $194,172.00 in company stock.

  • Percentage Held by Insiders

    Only 4.93% of the stock of Agios Pharmaceuticals is held by insiders.

  • Read more about Agios Pharmaceuticals' insider trading history.
Receive AGIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Agios Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AGIO Stock News Headlines

Agios Pharmaceuticals price target lowered to $52 from $54 at BofA
Trump Orders 'National Digital Asset Stockpile'
‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more traction
Zacks Research Issues Pessimistic Forecast for AGIO Earnings
See More Headlines

AGIO Stock Analysis - Frequently Asked Questions

Agios Pharmaceuticals' stock was trading at $32.86 at the beginning of 2025. Since then, AGIO shares have decreased by 15.8% and is now trading at $27.66.
View the best growth stocks for 2025 here
.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) issued its quarterly earnings results on Thursday, February, 20th. The biopharmaceutical company reported ($1.74) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.69) by $0.05. Agios Pharmaceuticals had a net margin of 1,845.92% and a negative trailing twelve-month return on equity of 2.51%.
Read the conference call transcript
.

Agios Pharmaceuticals' top institutional investors include Rhumbline Advisers (0.15%), Harbor Capital Advisors Inc. (0.06%) and GAMMA Investing LLC (0.01%). Insiders that own company stock include Jacqualyn A Fouse, Brian Goff, James William Burns, Sarah Gheuens, Cecilia Jones, Tsveta Milanova, David Scadden, Kaye I Foster-Cheek and Theodore James Jr Washburn.
View institutional ownership trends
.

Shares of AGIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Agios Pharmaceuticals investors own include Waste Connections (WCN), American Water Works (AWK), DiamondRock Hospitality (DRH), The RMR Group (RMR), AUO (AUOTY), iShares Micro-Cap ETF (IWC) and Voyager Therapeutics (VYGR).

Company Calendar

Last Earnings
2/20/2025
Today
4/18/2025
Next Earnings (Estimated)
5/01/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:AGIO
Fax
N/A
Employees
390
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$56.57
High Stock Price Target
$75.00
Low Stock Price Target
$46.00
Potential Upside/Downside
+104.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.56
Research Coverage
9 Analysts

Profitability

Trailing P/E Ratio
2.44
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$673.72 million
Net Margins
1,845.92%
Pretax Margin
1,967.15%

Debt

Sales & Book Value

Annual Sales
$36.50 million
Price / Cash Flow
N/A
Book Value
$27.02 per share
Price / Book
1.02

Miscellaneous

Free Float
54,471,000
Market Cap
$1.58 billion
Optionable
Optionable
Beta
0.83

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

This page (NASDAQ:AGIO) was last updated on 4/18/2025 by MarketBeat.com Staff
From Our Partners